BGM Stock Price, Chart, Stats & News

BGM chart
Fundamentals
Gross margin | 16.39% |
Operating margin | -2.25% |
Pretax margin | -8.52% |
Net margin | -5.75% |
Effective tax rate | 29.01% |
ROA | -2.72% |
ROE | -3.37% |
D/E | – |
Interest coverage ratio | -0.88x |
BGM valuation
P/E | – |
P/S | 3.76x |
P/B | 0.08x |
P/CF | 6.24x |
P/FCF | -27.83x |
P/OCF | 6.24x |
PEG | -0.02x |
EV multiple | 118.28x |
About
Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions. BGM also provides Qilian Shan oxytetracycline tablets, formulated to prevent and treat a range of ailments in poultry (chickens, turkeys), livestock (cattle, swine), and humans, in addition to Qilian Shan oxytetracycline APIs for use by pharmaceutical manufacturers.
Similar securities
Based on sector and market capitalization











